2023 World Conference on Lung Cancer (Posters)-P2.13. Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC

P2.13. Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC - PDF(Abstract)

Pdf Summary

This study aimed to identify biomarkers that can predict the efficacy of PD-L1 inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The researchers analyzed 251 patients who were diagnosed with ES-SCLC and received PD-L1 combination chemotherapy. They collected baseline clinical features and blood tests before the treatment and calculated various biomarkers, including NLR, PLR, and SII. The impact of these biomarkers on progression-free survival (PFS) and overall survival (OS) was analyzed.<br /><br />The results showed that lower NLR was associated with better OS and PFS. Lower PLR was associated with better PFS but not with OS. Lower SII was associated with better PFS but not with OS. Higher HGB levels predicted better OS and PFS, while lower LDH levels were associated with good OS and PFS. Liver metastases predicted poor OS and PFS, while bone metastases also predicted poor OS. Brain metastasis did not have prognostic value.<br /><br />Multivariate analysis showed that high LDH, low HGB, and liver metastasis were independent factors for poor PFS and OS. The researchers concluded that higher LDH, lower HGB, and liver metastasis were independent predictors of poor efficacy for PD-L1 inhibitors in ES-SCLC. They also suggested that the correlation between lower NLR, PLR, and SII with PD-L1 efficacy should be further explored.<br /><br />In summary, this study identified several biomarkers that can help predict the efficacy of PD-L1 inhibitors in patients with ES-SCLC. Understanding these biomarkers can assist in selecting the most effective treatment strategies for these patients.

Asset Subtitle

Xinghao Ai

Meta Tag

Speaker Xinghao Ai

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

biomarkers

PD-L1 inhibitors

chemotherapy

ES-SCLC

NLR

PLR

SII

progression-free survival

overall survival

treatment strategies